VivoSeq
Nephrology

Focal Segmental Glomerulosclerosis

47

Pipeline Programs↗

6

Active Trials↗

26

Companies Involved↗

Focal Segmental Glomerulosclerosis is a moderately active landscape with 47 programs across 26 companies. The most active players are Alnylam Pharmaceuticals, Aurinia Pharmaceuticals, Bristol-Myers Squibb. 5 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

15/100

Mech. Concentration

11/100

Completion Rate

72/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 1Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2T

Tenet Medicines

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

40 of 49 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody714%Protein / enzyme12%Peptide12%

Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 98% of 52 pipeline programs.

Analysis

Trial Status

40

clinical trials

Completed23 · 57%
Terminated7 · 18%
Recruiting4 · 10%
Active, not recruiting2 · 5%
Withdrawn2 · 5%
Unknown status2 · 5%

Clinical Trials

Trial Activity

40 trials

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Recruiting·Sanofi logoSanofi·Phase 2·NCT06500702·84 enrolled
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Recruiting·NNational Human Genome Research Institute (NHGRI)·Phase 2·NCT06664814·30 enrolled
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis
Recruiting·AAkebia Therapeutics·Phase 2·NCT07268638·60 enrolled
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT07220083·286 enrolled
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Active, not recruiting·TTravere Therapeutics, Inc.·Phase 3·NCT03493685·371 enrolled
ALIGN: Sparsentan in FSGS
Active, not recruiting·Takeda logoTakeda·Phase 3·NCT06100001·370 enrolled
Permeability Factor in Focal Segmental Glomerulosclerosis
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1/2·NCT00007475·15 enrolled
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Completed·UUniversity of Michigan·Phase 2·NCT04009668·7 enrolled
Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)
Completed·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 3·NCT00981838·24 enrolled
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001959·21 enrolled
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
Completed·Sanofi logoSanofi·Phase 2·NCT01665391·36 enrolled
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT05213624·67 enrolled
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Completed·CComplexa, Inc.·Phase 2·NCT03422510·33 enrolled
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00004990·20 enrolled
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00135811·207 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)